Last updated: February 4, 2026
Case Overview:
MSP Recovery Claims Series LLC filed a patent infringement lawsuit against Amgen, Inc. in the U.S. District Court for the Southern District of Florida. The case was initiated on January 23, 2020, under docket number 1:20-cv-20549. The central dispute concerns Amgen's alleged infringement of MSP's patent rights related to biologic drug manufacturing or related processes.
Litigation Background:
MSP Recovery Claims Series LLC holds patents that cover specific biologic manufacturing methods or processes. The firm asserts that Amgen’s biologic drugs, likely including products like Repatha or others in similar classes, infringe on its patents. MSP claims damages and seeks injunctive relief to prevent further infringement.
Major Movements and Court Proceedings:
- Initial Complaint (January 2020): MSP alleges that Amgen's biologic products infringe multiple patents owned by MSP. It cites specific claims related to manufacturing processes that are allegedly utilized without authorization.
- Amgen’s Response (March 2020): Amgen filed a motion to dismiss or transfer, asserting that MSP’s patents are invalid, or that jurisdiction is improper. Amgen also challenged the patent validity based on prior art references.
- Case Management and Discovery (2020-2021): The court ordered preliminary disclosures, document exchange, and expert disclosures. Both parties engaged in depositions, with significant focus on the patent claims’ validity and infringement.
- Patent Validity Challenges: Amgen filed multiple motions for summary judgment on the basis of patent invalidity under 35 U.S.C. § 101 (patent eligibility), § 102 (novelty), and § 103 (non-obviousness).
- Motions and Hearings: The court addressed motions to dismiss and for summary judgment during late 2021 and 2022. The court's rulings on these motions shaped the scope of the damages claims and potential infringement findings.
- Recent Developments (2022-2023): The case remains active with the court scheduling further hearings, including potential Markman hearings on claim interpretation, and preparing for trial.
Legal Issues:
- Patent Validity: Amgen challenges MSP’s patents on grounds including obviousness, anticipation, and patentable subject matter.
- Infringement: MSP claims Amgen’s biologic drugs infringe patent claims covering manufacturing methods.
- Jurisdiction and Venue: Amgen contests the appropriateness of the Southern District of Florida, citing jurisdictional issues.
- Claim Construction: Ongoing disputes over the meaning of key patent claims, potentially impacting infringement and validity.
Potential Outcomes and Impacts:
- If MSP prevails on infringement but invalidates its patent claims, damages could be limited or null.
- A ruling in favor of Amgen on validity issues could nullify MSP’s claims entirely.
- A settlement or licensing agreement remains a possibility, especially given the high stakes for biologics companies.
Implications for Industry:
This case exemplifies ongoing patent litigation strategies in biologic drug development, especially targeting process patents. Companies are increasingly scrutinizing process patents' scope in light of the evolving patent law landscape, particularly around patent eligibilities under 35 U.S.C. § 101.
Key Dates & Deadlines:
- Complaint filed: January 23, 2020
- Amgen’s motion to dismiss: March 2020
- Summary judgment motions: late 2021
- Claim construction hearing: scheduled for mid-2023
- Trial date (potential): late 2023 or early 2024
Legal Context & Trends:
The case underscores complexities in biologic patent enforcement, with courts scrutinizing patent claims for patent eligibility, especially in the context of innovations in biologic manufacturing. Recent Federal Circuit decisions emphasize the importance of precise claim language and robust patent drafting strategies.
Key Takeaways:
- The case hinges on patent validity and infringement, with significant procedural motions influencing potential outcomes.
- Amgen's challenge on patent invalidity could reshape MSP’s litigation strategy if successful.
- The evolving jurisprudence on patent eligibility impacts how biologic process patents are litigated.
- Settlement negotiations may accelerate given the financial stakes involved.
- The case signals a broader trend of biologic patent enforcement and defensive patent invalidation strategies.
FAQs:
1. What are the main legal issues in MSP Recovery Claims Series LLC v. Amgen?
The primary issues are patent infringement and patent validity under 35 U.S.C. §§ 101, 102, and 103. The court is also addressing claim construction and jurisdiction.
2. How does patent invalidity challenge impact the case?
If Amgen successfully invalidates MSP’s patents, MSP’s infringement claims become moot, potentially ending the litigation or prompting settlement.
3. Are process patents more vulnerable in recent rulings?
Yes, courts have become increasingly scrutinizing process patents’ patent eligibility, particularly after recent Federal Circuit decisions emphasizing the need for clear, specific claims.
4. Will this case set a precedent for biologic patent litigation?
It could influence future disputes, especially regarding the scope of process patents and the importance of claim language and patent standards.
5. What are the likely next steps?
A claim construction hearing is scheduled, with trial anticipated in late 2023 or early 2024. The parties may also engage in settlement negotiations.
Sources:
[1] PACER Court Records, Case No. 1:20-cv-20549, Southern District of Florida.
[2] Federal Circuit decisions on biologic patent eligibility.
[3] Industry reports on biologic patent litigation trends.
